Elevai Labs Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Graydon Bensler
Chief executive officer
US$110.0k
Total compensation
| CEO salary percentage | 77.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | no data |
| Board average tenure | 1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$5m |
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | n/a | n/a | -US$5m |
| Dec 31 2023 | US$110k | US$85k | -US$4m |
| Sep 30 2023 | n/a | n/a | -US$4m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | -US$3m |
| Dec 31 2022 | US$85k | US$85k | -US$2m |
Compensation vs Market: Graydon's total compensation ($USD110.00K) is below average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Graydon's compensation has increased whilst the company is unprofitable.
CEO
Graydon Bensler (33 yo)
less than a year
Tenure
US$110,000
Compensation
Mr. Graydon Bensler, CFA, is Independent Director of Qualigen Therapeutics, Inc. from November 13, 2024. Mr. Bensler serves as Chief Financial Officer, Secretary and Director of Elevai Labs Inc (formerly k...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | no data | US$110.00k | 0.16% $ 16.9k | |
| Independent Director | 1.4yrs | no data | 0.0080% $ 837.6 | |
| Independent Director | 1.4yrs | no data | 0.00023% $ 23.9 | |
| Independent Director | less than a year | no data | no data | |
| Non-Executive Chairman | less than a year | no data | 0.32% $ 33.3k | |
| Director | no data | US$200.00k | 0.55% $ 57.5k |
1.0yrs
Average Tenure
39yo
Average Age
Experienced Board: ELAB's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.